# Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Study · id `cardio:ct-nct03434119` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03434119](<https://clinicaltrials.gov/study/NCT03434119>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03434119

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 241 participants.

## Technical summary

Registry record NCT03434119. Randomized; no masking; primary purpose treatment. Start 2018-02-20 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-01-13.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 241 participants (enrolled count; ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Started: 2018-02-20 (actual) (ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Primary completion: 2019-01-07 (actual) (ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Completion: 2019-01-07 (actual) (ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Results first posted: 2020-01-13 (ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03434119, source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03434119-2022-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
- Acronym: LixiLan-D
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Insulin glargine/Lixisenatide
- Intervention (Drug): Insulin glargine (HOE901)
- Intervention (Drug): Background therapy
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

## Provenance

Content hash: efb0a0793dc4db9d1c28cd168c9b8c25f8aa7b4fc15495846d1df2220139b422
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
